Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Perioperative Toripalimab Combined With Recombinant Human Endostatin as Postoperative Adjuvant Therapy for Clinical Stage II Malignant Melanoma: A Multicenter, Single-Arm, Phase II Clinical Study

NCT06965231 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06965231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06965231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Perioperative Toripalimab Combined With Recombinant Human Endostatin as Postoperative Adjuvant Therapy for Clinical Stage II Malignant Melanoma: A Multicenter, Single-Arm, Phase II Clinical Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
March 30, 2029
Enrollment
58 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acral melanoma, melanoma of skin, stage ii melanoma